Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 36
Selected: 0
NCT IDTitle
NCT03380039Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma
NCT05393986Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors
NCT03146234CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma
NCT06560827CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
NCT04756648Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma
NCT05838131Study of CT071 Injection in RRMM or PPCL
NCT04581473Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
NCT06822881CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)
NCT03915184Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
NCT04404595Claudin18.2 CAR-T (CT041) in Patients with Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers
NCT03302403Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
NCT05893693Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
NCT06988059A Study of CT0596 in Plasma Cell Leukemia
NCT02933775CD19-redirected Autologous Cells (CAR-CD19 T Cells)
NCT02876978Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma
NCT03975907Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
NCT06333509Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL
NCT03716856Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma
NCT06730256A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
NCT039802884th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3
NCT04963959PBMC Collection for Production of UCAR T Cells
NCT05822037CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
NCT03994913Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma
NCT05911217A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
NCT03159819Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma
NCT05066022A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT06659770A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma
NCT07031713Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE
NCT07033299The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis
NCT06718270a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
NCT03874897Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
NCT06407947Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
NCT06825845Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy
NCT04400383Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
NCT04973098Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma
NCT03884751Chimeric Antigen Receptor T Cells Targeting Glypican-3